Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 286 posts found.

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023
Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …

News

BMS acquires Mirati Therapeutics for $4.8bn

October 9, 2023
Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology

Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …

News

BMS shares new research and development  plans at the company’s R&D day

September 15, 2023
Research and Development BMS, Pharmacy, R&D, development, research

Bristol Myers Squibb (BMS) recently held a Research and Development (R&D) Day in New York, US, in order to discuss …

News

BMS follow-up data sees long-term survival for melanoma patients

May 24, 2021
Sales and Marketing BMS, skin cancer

Bristol Myers Squibb (BMS) has announced follow-up data from their Phase III CheckMate-067 clinical trial, which demonstrated that 49% of …

News

NICE shoots down Bristol-Myers Squibb immunotherapy Opdivo for post-surgery skin cancer

November 5, 2020
Sales and Marketing BMS, Cancer, NHS, NICE, opdivo

NICE has rejected the routine use of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) on the NHS in England and Wales for …

News

Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis

November 4, 2020
Research and Development BMS, deucravacitinib, plaque psoriasis

Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …

News
reblozyl

Canadian approval for Reblozyl for transfusion-dependent anaemia in beta-thalassemia patients

September 29, 2020
Manufacturing and Production, Sales and Marketing BMS, Canada, Reblozyl

Bristol Myers Squibb and Acceleron have managed to secure regulatory approval in Canada for Reblozyl (luspatercept) for the treatment of …

News
bristolll

Phase 3 kidney cancer trial of Bristol Myers Squibb’s Opdivo and Exelixis’ Cabometyx meets primary endpoint

April 21, 2020
Manufacturing and Production BMS, Bristol-Myers Squibb, Exelixis, bristol myers squibb

Bristol Myers Squibb and Exelixis have announced that the Phase 3 trial investigating the combination of Opdivo (nivolumab) and Cabometyx …

News
fda2outsideweb

FDA approval for BMS and Acceleron’s Reblozyl to reduce red blood cell transfusion dependence

April 6, 2020
Manufacturing and Production, Sales and Marketing BMS, FDA, Reblozyl, pharma

The FDA has given the regulatory thumbs-up in the US of Reblozyl (luspatercept-aamt), the “first and only erythroid maturation agent” …

News
humacao_exterior

BMS pulls Opdivo+Yervoy combo in EU for advanced non-small cell lung cancer

February 3, 2020
Sales and Marketing BMS, Cancer, Europe, Yervoy, lung cancer, opdivo

Bristol-Myers Squibb has confirmed it has withdrawn its application with the European Commission for its combination of Opdivo (nivolumab) and …

News
opdivo_1_1

EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …

News
opdivo_1_1

BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme

September 5, 2019
Research and Development BMS, glioblastoma multiforme, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the …

News

Catalent to purchase Italy manufacturing facility from BMS

June 20, 2019
Manufacturing and Production, Sales and Marketing BMS, Bristol-Myers Squibb, Cataletnt, pharma

Bristol-Myers Squibb has reached an agreement with Catalent for the latter to acquire its Anagni, Italy-based facility which specialises in …

News
mercier

Long term BMS exec Johanna Mercier joins Gilead as new Chief Commercial Officer

May 30, 2019
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Gilead, cco, commercial, pharma

Gilead Sciences have said Bristol-Myers Squibb exec Johanna Mercier will be the firm’s new Chief Commercial Officer. In her new …

News
top_10_image

Top Ten most popular articles on Pharmafile.com this week!

May 17, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Gilead, J&J, JJ, Janssen, Mundipharma, Novartis, Teva, generics

Some big names – including Gilead, Janssen, Teva and Bristol-Myers Squibb – were in trouble this week after two separate …

News

Latest content

Ardena announces €20m expansion following first GMP approval

April 19, 2024

Roche’s Alecensa approved by FDA as lung cancer treatment

April 19, 2024

GSK shares results from phase 3 trial for gonorrhoea treatment

April 18, 2024

Eli Lilly’s tirzepatide demonstrates efficacy in reducing sleep apnoea severity

April 18, 2024

Medincell and AbbVie enter agreement for development of next-generation injectables

April 17, 2024